nach oben

Die Diabetologie

Erschienen in:

06.04.2024 | Fettleber | DDG Praxisempfehlungen

Diabetes und Fettleber

verfasst von: Prof. Dr. med. Norbert Stefan, Prof. Dr. Dr. h. c. med. univ. Michael Roden

Erschienen in: Die Diabetologie | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://www.ddg.info/behandlung-leitlinien/leitlinien-praxisempfehlungen) befinden sich alle PDF zum kostenlosen Download. …

Younossi ZM (2019) Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol 70:531–544CrossRefPubMed

Eigentler T, Lomberg D, Machann J et al (2020) Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 172:836–837CrossRefPubMed

Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904CrossRefPubMed

Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7:313–324CrossRefPubMed

Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684–694CrossRefPubMed

Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRefPubMed

Roeb E, Canbay A, Bantel H et al (2022) Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021-025. Z Gastroenterol 60:1346–1421CrossRefPubMed

European Association for the Study of the Liver (EASL), European European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140CrossRef

European Association for the Study of the Liver. (2021) EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol 75:659–689CrossRef

10.

Younossi ZM, Corey KE, Alkhouri N et al (2020) Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 52:513–526CrossRefPubMed

11.

Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32–42CrossRefPubMed

12.

Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357CrossRefPubMed

13.

Bril F, McPhaul MJ, Caulfield MP et al (2019) Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 67:303–311CrossRefPubMed

14.

Eslam M, Sanyal AJ, George J et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158:1999–2014.e1CrossRefPubMed

15.

Roden M, Shulman GI (2019) The integrative biology of type 2 diabetes. Nature 576:51–60CrossRefPubMed

16.

Stefan N, Cusi K (2022) A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 10:284–296CrossRefPubMed

17.

Younossi ZM, Rinella ME, Sanyal AJ et al (2021) From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73:1194–1198CrossRefPubMed

18.

Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654.e1‑9CrossRefPubMed

19.

Adams LA, Anstee QM, Tilg H et al (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153CrossRefPubMed

20.

Aminian A, Al-Kurd A, Wilson R et al (2021) Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326:2031–2042CrossRefPubMedPubMedCentral

21.

Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124CrossRefPubMed

22.

Loomba R, Abdelmalek MF, Armstrong MJ et al (2023) Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8:511–522CrossRefPubMedPubMedCentral

23.

Francque SM, Bedossa P, Ratziu V et al (2021) A Randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385:1547–1558CrossRefPubMed

24.

Harrison SA, Bashir MR, Guy CD et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394:2012–2024CrossRefPubMed

25.

Loomba R, Sanyal AJ, Kowdley KV et al (2023) Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med 389:998–1008CrossRefPubMedPubMedCentral

Titel: Diabetes und Fettleber
verfasst von: Prof. Dr. med. Norbert Stefan
Prof. Dr. Dr. h. c. med. univ. Michael Roden
Publikationsdatum: 06.04.2024
Verlag: Springer Medizin
Schlagwörter: Fettleber
Typ-2-Diabetes
Erschienen in: Die Diabetologie / Ausgabe 3/2024
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-024-01170-4

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Mitteilungen des BDI

Pharmakotherapie der Adipositas

Empfehlungen zur Ernährungsprävention des Typ‑2‑Diabetes mellitus

Diabetische Retinopathie: Epidemiologie, Stadien, Diagnostik, Screening und Therapie

Empfehlungen zur Ernährung von Personen mit Typ-2-Diabetes mellitus

Pathophysiologie der Adipositas

Praxisempfehlungen der Deutschen Diabetes Gesellschaft